Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
All News
Article
The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety signals
Article
A retrospective analysis of the ACR RISE registry shows that multimorbidity is not only common in patients with active rheumatoid arthritis (RA), but also impacts treatment choices and outcomes.
Article
An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).
Article
Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.
Article
Disease activity leads to poor outcomes; but does comorbidity add to this? A recent analysis suggests that while comorbidities do not affect long-term, functional outcomes, sociodemographic factors do affect outcomes in rheumatoid Arthritis (RA).
Article
MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination.
Article
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Article
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
Article
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush
Tweet
Metanalysis of Colchicine in oronary artery disease (CAD) (13RCTs, n=13125), colchicine signif. reduces the risk of MI (OR 0.64) & CVA/TIA (OR 0.50), but has a higher rate of GI upset with no influence on all‐cause mortality (OR 0.96) https://t.co/CRDUFsc6lG
Peter Nash
Tweet
Biomarkers predict early ILD in systemic sclerosis: https://t.co/9z4Swjjy4p we need a biomarker for early disease!
Dr. John Cush
Tweet
Worth another share--
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/7QtynRKAd6
Dr. John Cush
Tweet
ICYMI
While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/sJpbzIbBJt
Dr. John Cush
Tweet
Pirfenidone, studied in 127 pts w/ CVD/CTD ILD, fibrotic interstitial pneumonia, chr hypersensitivity pneumonitis, & asbestoslung fibrosis. Pirefenidone had significantly less FVC% decline compared with placebo (p=0·043)
https://t.co/H1s6ut4NhG
Dr. John Cush
Tweet
263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stablized their FVC, DLCO, CHest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/1dGufcKsha
Dr. John Cush
Tweet
Serious problem! Pulmonologists believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/vUyCxJP2Mh
Dr. John Cush
Tweet
Stroke risk is increased in arthritis (RR 1.36, 95% CI: 1.27–1.46); esp for RA (RR 1.38), AS (RR 1.49), PsA (1.33) & gout (1.40); but NOT osteoarthritis (RR=1.03). Apparently Inflammation drives this risk. https://t.co/Snb6OrtZJH
